Thrombotic and thromboembolic phenomena are one of the leading complications and causes of poor outcomes in COVID-19 patients admitted to hospital [1]. In the pathophysiology of pulmonary and endothelial damage due to SARS-CoV-2 infection, an inflammatory and prothrombotic state with microvascular thrombosis has been described [2]. Therefore, early initiation of therapeutic low molecular weight heparin (LMWH) doses could be more effective than prophylactic doses not only in preventing thrombotic/thromboembolic complications (due to its anticoagulant effect), but also in improving overall outcomes (due to its anti-inflammatory properties) in patients admitted to hospital with non-severe COVID-19 pneumonia.
